Valeant Pharmaceuticals International (VRX) : The total money flow in Valeant Pharmaceuticals International (VRX) was negative ($6.22 million), showing the domination of sellers in the Friday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $74.5 million. Transactions on upticks were comparatively lower at $68.29 million. The uptick to downtick ratio was 0.92. The total block trades done on upticks were valued at $4.17 million. The total block trades on downticks were valued at $5.63 million. The uptick to the downtick ratio of block trades was 0.74. The money flow during block trades was negative ($1.46 million) when the stock traded with a gain of $14 cent. Valeant Pharmaceuticals International (VRX) was $29.26, an increase of 0.48% over the previous days close.
The company Insiders own 16.37% of Valeant Pharmaceuticals International shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 23.12% . Institutional Investors own 63.69% of Valeant Pharmaceuticals International shares. During last six month period, the net percent change held by insiders has seen a change of 9.23%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Valeant Pharmaceuticals International, Inc., Karabelas Argeris N, had purchased 4,000 shares in a transaction dated on August 11, 2016. The transaction was executed at $24.65 per share with total amount equaling $98,600.
Valeant Pharmaceuticals International (NYSE:VRX): stock was range-bound between the intraday low of $28.03 and the intraday high of $29.32 after having opened at $29.28 on Fridays session. The stock finally closed in the red at $29.28, a loss of -1.24%. The stock remained in the red for the whole trading day. The total traded volume was 19,162,985 shares. The stock failed to cross $29.32 in Fridays trading. The stocks closing price on Thursday was $29.12.
Valeant Pharmaceuticals International (VRX) has risen sharply, recording gains of 30.97% in the past 4 weeks. However, the stock has corrected -6.71% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 31.14% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.